AVI BioPharma, Inc. (NASDAQ:AVII)

CAPS Rating: 4 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Recs

0
Player Avatar Maribaza (26.67) Submitted: 7/16/2010 12:27:08 PM : Underperform Start Price: $1.86 AVII Score: +84.40

29,25,061,70,96

Report this Post Reply

Featured Broker Partners


Advertisement